Dario Bencivelli

Dario Bencivelli

Auto-generated profile, based on publicly available information

Dario Bencivelli

Department of Medical Sciences, Section of Dermatology University of Ferrara Ferrara Italy

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2013 in Acta Neurologica Scandinavica
Verified
Journal Article
Closed access
PDF file
ICIlaria Casetta
Ilaria Casetta
Fabrizio VincenziFabrizio Vincenzi
Fabrizio Vincenzi
DBD. Bencivelli
D. Bencivelli
CCCarmen Corciulo
Carmen Corciulo
MGM. Gentile
M. Gentile
Katia VaraniKatia Varani
Katia Varani
Objectives In the last decade, increasing evidence suggests a key role of adenosine in Parkinson's disease (PD) and A2A adenosine receptors (A2AARs) as an important pharmacological target in PD. An overexpression of A2AARs has been found in putamen and in peripheral blood cells of PD patients. The primary aim of this study was to verify whether the alterations in A2AARs in lymphocytes of PD subjects correlate with disease severity. Material and methods A consecutive sample of PD patients was enrolled. A clinical examination and a face‐to‐face interview were carried out. A2AARs were investigated to verify the affinity and receptor density in lymphocyte membranes. The data were compared with those found in healthy controls. Moreover, the correlation between A2AAR density and affinity and clinical variables was evaluated in PD patients. Results In human lymphocyte membranes from PD patients, an increase in A2AAR density and a decrease in A2AAR affinity were found if compared with healthy subjects. A statistically significant correlation between the A2AAR density or affinity and specific clinical parameters as motor and cognitive impairment was detected. Patients with higher A2AAR density and lower affinity were more likely to exhibit motor complications. Conclusions Parkinson's disease patients show an A2AAR upregulation in lymphocyte membranes if compared with healthy subjects. The correlation found between A2AAR density or affinity and clinical parameters highlights the central role of A2AAR modulation in the pharmacological treatment for PD and could suggest the putative role of A2AAR as a candidate biomarker of PD severity.

4 January 2021 in Contact Dermatitis
Verified
Journal Article
Open access
PDF file
MCMonica Corazza
Monica Corazza
DBDario Bencivelli
Dario Bencivelli
PZPierantonia Zedde
Pierantonia Zedde
AMAlberto Monti
Alberto Monti
MZMaria R. Zampino
Maria R. Zampino
ABAlessandro Borghi
Alessandro Borghi
Click on the article title to read more.

20 February 2021 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
MCMonica Corazza
Monica Corazza
DBDario Bencivelli
Dario Bencivelli
MCMartina Catani
Martina Catani
ACAlberto Cavazzini
Alberto Cavazzini
LMLucia Mantovani
Lucia Mantovani
ABAlessandro Borghi
Alessandro Borghi

15 February 2022 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
Daria BortolottiDaria Bortolotti
Daria Bortolotti
MCMonica Corazza
Monica Corazza
ARAntonella Rotola
Antonella Rotola
DBDario Bencivelli
Dario Bencivelli
GSGiovanna Schiuma
Giovanna Schiuma
ABAlessandro Borghi
Alessandro Borghi
KIR2DL2, an inhibitory Killer cell Immunoglobulin-like Receptor (KIR), has been shown to predispose to the development of several herpesvirus-associated diseases by inhibiting the efficiency of Natural Killer (NK) cells against virus-infected cells. The aim of this observational study was to assess the prevalence of KIR2DL2 and Human Herpes Virus 8 (HHV8) in patients affected with classical and endemic Kaposi sarcoma (KS), as well as in controls. Blood samples collected from 17 Caucasian, HIV-negative, immunocompetent patients affected with classical KS (c-KS), 12 African, HIV-negative patients with endemic KS (e-KS), 83 healthy subjects and 26 psoriatic patients were processed for genotypization by PCR for two KIR alleles, such as KIR2DL2 and KIR2DL3 and analyzed for HHV-8 presence. The totality of both c-KS and e-KS patients presented HHV-8 infection, whereas HHV8 was found in 26.9% of psoriatic subjects and 19.3% of healthy subjects. KIR2DL2 was found in the 76.5% of c-KS subjects, while the receptor was found in 41.7% of the e-KS group, 34.6% of psoriatic patients and 43.4% of healthy controls (p < 0.0001). A significantly higher prevalence of KIR2DL2 in c-KS patients than in all the other subjects was also confirmed comparing age-matched groups. Based on these results, the inhibitory KIR2DL2 genotype appears to be a possible cofactor which increases the risk of developing c-KS in HHV8-positive, immunocompetent subjects, while it seems less relevant in e-KS pathogenesis.

6 March 2020 in Contact Dermatitis
Verified
Journal Article
Closed access
PDF file
MCMonica Corazza
Monica Corazza
DBDario Bencivelli
Dario Bencivelli
MLMaria M. Lauriola
Maria M. Lauriola
VSValeria Scuderi
Valeria Scuderi
ABAlessandro Borghi
Alessandro Borghi

6 January 2022 in Research Square
Verified
Preprint
Open access
PDF file
DBDaria Bortolotti
Daria Bortolotti
MCMonica Corazza
Monica Corazza
ARAntonella Rotola
Antonella Rotola
DBDario Bencivelli
Dario Bencivelli
GSGiovanna Schiuma
Giovanna Schiuma
ABAlessandro Borghi
Alessandro Borghi
KIR2DL2, an inhibitory Killer cell Immunoglobulin-like Receptor (KIR), has been shown to predispose to the development of several herpesvirus-associated diseases by inhibiting the efficiency of Natural Killer (NK) cells against virus-infected cells. The aim of this observational study was to assess the prevalence of KIR2DL2 and Human Herpes Virus 8 (HHV8) in patients affected with classical and endemic Kaposi sarcoma (KS), as well as in controls. Blood samples collected from 17 Caucasian, HIV-negative, immunocompetent patients affected with classical KS (c-KS), 12 African, HIV-negative patients with endemic KS (e-KS), 83 healthy subjects and 26 psoriatic patients were processed for genotypization by PCR for two KIR alleles, such as KIR2DL2 and KIR2DL3 and analyzed for HHV-8 presence. The totality of both c-KS and e-KS patients presented HHV-8 infection, whereas HHV8 was found in 26.9% of psoriatic subjects and 19.3% of healthy subjects. KIR2DL2 was found in the 76.5% of c-KS subjects, while the receptor was found in 41.7% of the e-KS group, 34.6% of psoriatic patients and 43.4% of healthy controls (p<0.0001). A significantly higher prevalence of KIR2DL2 in c-KS patients than in all the other subjects was also confirmed comparing age-matched groups. Based on these results, the inhibitory KIR2DL2 genotype appears to be a possible cofactor which increases the risk of developing c-KS in HHV8-positive, immunocompetent subjects, while it seems less relevant in e-KS pathogenesis.